<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124207">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01681173</url>
  </required_header>
  <id_info>
    <org_study_id>DDS-FKZ 232/11/08</org_study_id>
    <nct_id>NCT01681173</nct_id>
  </id_info>
  <brief_title>OPTIFIT-Optimal Fiber Trial for Diabetes Prevention</brief_title>
  <official_title>Investigation of the Effect of Insoluble Dietary Fiber on Carbohydrate and Lipid Metabolism and the Prevention of Diabetes Mellitus Type 2 in Subjects With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Institute of Human Nutrition</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Diabetes Foundation, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Ernst von Bergmann, Potsdam, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Institute of Human Nutrition</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High intake of insoluble fiber is strongly associated with a reduced incidence of diabetes
      and cardiovascular events in prospective observation studies. Our primary objective is to
      compare a life style diabetes prevention program(PRAEDIAS) with and without added insoluble
      fibers in its effectiveness to prevent incident diabetes type 2 in high risk individuals
      with impaired glucose tolerance. Subjects with IGT not willing to participate in the
      intervention will be used as independent controls. Secondary aims are to identify mechanisms
      of action with regard to body composition, anti-inflammatory and metabolic effects of
      fibers. We propose a randomized, prospective intervention study. The results will be of
      general relevance for guidance of fiber intake in the population and will help the food
      industry to design healthy high fiber foods. Fiber can be added at low cost to numerous
      foods. Increased fiber intake may therefore provide a simple non-cognitive prevention
      strategy effective at the population level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective is to investigate whether insoluble fibers added to standard nutrition
      can reduce the progression of impairment of glucose metabolism in a high risk population
      with impaired glucose metabolism. Large prospective cohort studies clearly show that mainly
      insoluble cereal fiber from whole grains is associated with reduced risk of type 2 diabetes
      and cardiovascular disease. However, there is a lack of evidence from prospective
      intervention studies targeted to evaluate the potential of dietary fibers to reduce diabetes
      and cardiovascular disease as recently stated by the Cochrane Foundation. Dietary fiber
      intake is generally much lower than currently recommended, which may in part be related to
      side effects of whole grain nutrients and their gustatory properties. Intestinally
      uncomfortable effects are at least partly related to fermentation which is much less induced
      by insoluble non-fermentable fibers than by soluble fermentable fibers. The prospective
      demonstration of beneficial effects of insoluble fibers in preventing diabetes type 2 will
      allow detailed nutritional recommendations. This may serve to support the consumption of
      metabolically beneficial constituents of fiber-rich diets and help to increase fiber intake
      by high fiber natural nutrients or everyday nutrients enriched in insoluble natural fibers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change of 2h-postprandial blood glucose from IGT to diabetes mellitus type 2 or normal glucose tolerance (NGT)</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of the glucose metabolism (OGTT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of insulin sensitivity</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement by HOMA and OGIS from the OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of insulin secretion</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement by the OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of inflammatory markers in blood</measure>
    <time_frame>0, 6, 12, 18, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CRP, leukocytes, adipocytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biometric data</measure>
    <time_frame>0, 6, 12, 18, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nutritional impact of blood pressure, anthropometry (body weight and body composition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cognitive performance</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of indices for the prediction of fat mass</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of fat fraction in liver, abdominal and in the total body fat measuring by MRI/H1-spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of gene expression in adipose tissue</measure>
    <time_frame>0, 12, 24 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of inflammatory and other transcripts in sc adipose tissue in a fat biopsy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes</condition>
  <condition>Nutrition Disorders</condition>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <condition>Metabolic Syndrome x</condition>
  <condition>Body Weight</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>Drink enriched in fibers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7,5g enriched fiber drinks, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo drink, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fiber</intervention_name>
    <description>200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months</description>
    <arm_group_label>Drink enriched in fibers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200ml Placebo, BID, over 24 months</description>
    <arm_group_label>Placebo drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance

          -  Age&gt;18years old

          -  both gender

        Exclusion Criteria:

          -  Diabetes type 1 and type 2

          -  chronic or malignant disease

          -  Intake of metabolic influence drugs

          -  Food allergies, fiber intolerance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas FH Pfeiffer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Institute of Human Nutrition Potsdam-Rehbruecke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Honig</last_name>
    <phone>+493084453362</phone>
    <email>caroline.honig@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hornemann Silke, MD</last_name>
    <phone>+4933200882791</phone>
    <email>silke.hornemann@dife.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German Instiute of Human Nutrition</name>
      <address>
        <city>Potsdam-Rehbruecke</city>
        <state>Nuthetal</state>
        <zip>14558</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas FH Pfeiffer, Prof.</last_name>
      <phone>+4933200882771</phone>
      <email>afhp@dife.de</email>
    </contact>
    <contact_backup>
      <last_name>Silke Hornemann, MD</last_name>
      <phone>+4933200882791</phone>
      <email>silke.hornemann@dife.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas FH Pfeiffer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margrit Kemper, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silke Hornemann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite University</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas FH Pfeiffer, Prof.</last_name>
      <phone>+493084452114</phone>
      <email>afhp@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Honig Caroline</last_name>
      <phone>+493084453362</phone>
      <email>caroline.honig@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas FH Pfeiffer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Honig</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 5, 2012</lastchanged_date>
  <firstreceived_date>September 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Institute of Human Nutrition</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Andreas F. H. Pfeiffer</investigator_full_name>
    <investigator_title>Chief, Department of Clinical Nutrition</investigator_title>
  </responsible_party>
  <keyword>Nutritional support</keyword>
  <keyword>Diet therapy</keyword>
  <keyword>Diabetes prevention</keyword>
  <keyword>Insoluble fiber</keyword>
  <keyword>Healthy life style</keyword>
  <keyword>Weight loss</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
